Beyond Model Organisms Engineering Revolution

[SOFIA] Okay, quick thought experiment. Pick any organism on Earth that does something genuinely wild — makes an antibiotic, survives in sea ice, lives inside a plant root — and now try to reprogram it. Ninety-nine times out of a hundred, you can't. Not because the biology's boring, but because you have no tools. No way to get DNA in, no plasmid that replicates, no promoter you trust.

[DANIEL] Which is a strange bottleneck when you think about it. We've had E. coli and baker's yeast as workhorses for decades. Everything we know about genetic engineering, we basically learned in those two.

[SOFIA] Right, and they're great! But they're maybe the most boring organisms on the planet. So today's arc is about the creatures worth meeting — the non-model organisms — and the slow, unglamorous work of building the tools that let us actually talk to them.

[DANIEL] Let's define the terms, because "non-model" is doing a lot of work there. A model organism is one the whole community has converged on — you've got a sequenced genome, standardized strains, and critically, established ways to introduce DNA. For bacteria that's transformation, conjugation, electroporation. For eukaryotes it's transfection.

[SOFIA] And people mix those up constantly. You transform a bacterium. You transfect a mammalian cell. Different words, different biology.

[DANIEL] A non-model organism has none of that infrastructure. So the first question is always brutally practical — can I even get a piece of DNA inside this cell, and will it stay there and do something.

[SOFIA] So where does the arc start? For me it's 2020, and there are actually two papers that year coming at the same wall from opposite sides. Fatma and colleagues wrote this review on domesticating non-model microbes as cell factories — actinobacteria, cyanobacteria, yeasts, fungi — the bugs that make interesting chemicals and materials. And their thesis is basically: these organisms are "intractable" because we haven't built organism-specific tools yet. Especially CRISPR.

[DANIEL] And I want to flag what "intractable" really means, because it's not one problem. It's restriction-modification systems that chew up your incoming DNA. It's not having an origin of replication that works in that species. It's toxic promoters, bad codon usage. Every one of those is a separate wall.

[SOFIA] And the Fatma argument is that CRISPR changes the economics — once you can make targeted edits, you don't need the organism to be naturally cooperative, you force the edit.

[DANIEL] In principle. I'd push on how transferable that really is, because CRISPR still needs delivery and expression, which is the very thing that's hard. But as a framing, sure — tools, not luck.

[SOFIA] Now the other 2020 paper is the one I love, because it's a totally different culture of science. The marine protist transformation initiative. This was funded by the Moore Foundation — 41 research groups, 113 authors — and they systematically went after transformation in 39 marine protist species. Across every eukaryotic supergroup.

[DANIEL] Which is remarkable as an experimental design choice. Instead of one lab publishing one success and burying ten failures, they coordinated it and reported the failures too.

[SOFIA] Okay, this is the good stuff — they landed 13 first-ever protocols. First nuclear transformation of a dinoflagellate. First Antarctic diatom. And then they distilled everything, wins and dead ends, into a published transformation roadmap so the next lab doesn't start from zero.

[DANIEL] And that's the turning point, honestly. Not any single protocol — the roadmap. They converted transformation from folklore into something closer to a decision tree. When a negative result is reported at that scale, it actually has statistical value. You learn which approaches fail across a whole supergroup, not just in one grad student's hands.

[SOFIA] So 2020 gives us the thesis — build organism-specific tools — and a template for doing it collaboratively. Now watch what happens over the next four years, because the field splits into a few threads that all feed back in.

[DANIEL] The first is standardization. If every organism needs its own tools, you drown in one-offs unless the parts are modular.

[SOFIA] That's the de Vries 2024 cloning paper. So the background here — modular cloning, MoClo, is built on Golden Gate assembly. You use a type IIS restriction enzyme, which cuts outside its recognition site, so you can design custom overhangs and snap DNA parts together in a defined order, one pot, no scar.

[DANIEL] The catch being that standard MoClo overhangs are four base pairs, and they leave little scar sequences between parts. Fine for some things, a problem when you're assembling a clean transcription unit.

[SOFIA] Right, so they use SapI, which leaves a three-nucleotide overhang — and three lines up with a codon. So you get scarless, codon-based assembly of transcription units. And the piece I really like is the "Out-Cloning" — they generate the organism-specific acceptor plasmid on demand, from modular parts, for any organism.

[DANIEL] Which is the direct answer to the 2020 problem. Every non-model bug wants a different plasmid backbone — different origin, different markers. Instead of maintaining a huge library, you build the one you need from standard pieces.

[SOFIA] Then the second thread is CRISPRi in a real environment, and this one's gorgeous. Roghair Stroud and colleagues, Pseudomonas alloputida KT2440. CRISPRi — that's the dead-Cas9, dCas9, no cutting, it just parks on a gene and blocks transcription. Reversible knockdown instead of a permanent edit.

[DANIEL] And they integrated the dCas9 into the chromosome using a mini-Tn7 transposon, driven by the XylS/Pm system so you can induce it. That matters — a chromosomal single copy is more stable than a plasmid you might lose.

[SOFIA] And the headline is they did it in the rhizosphere. In situ gene repression in the actual root environment, not a shake flask. And they knocked down pyoverdine — the siderophore, the molecule Pseudomonas uses to scavenge iron and outcompete its neighbors — and could disable that competition on demand.

[DANIEL] That's the through-line landing. 2020 says build tools for the untamed organism. This is tools working in the messy place the organism actually lives.

[SOFIA] Then the third thread goes to extremes, literally. The polyextremophile engineering paper — organisms that survive multiple stresses at once. High salt, high radiation, cold, whatever.

[DANIEL] And their move is mechanistic reduction. They argue you don't need to model every extreme condition separately — there are four proximal stress mechanisms underneath all of them. Reactive oxygen species, covalent damage, protein fold destabilization, and membrane fluidity.

[SOFIA] So if you know which root causes a combination of stresses hits, you can predict whether adaptations will stack synergistically or fight each other. Rational design of a chassis for space in-situ resource use, or industrial biomanufacturing.

[DANIEL] It's a hypothesis-generating framework more than a proven catalog, and I'd want to see the predicted synergies tested. But it's the right kind of ambition — engineering the organism instead of just cataloging it.

[SOFIA] And then the arc closes on something lovely and humbling — Jody Deming's 2024 piece on Colwellia, the psychrophiles in sea ice. Cold-loving bacteria that exceed the temperature and metabolic limits people predicted for life in that environment.

[DANIEL] Which is a nice bookend. The polyextremophile paper is trying to design the extreme organism from principles. Colwellia is nature reminding us the real ones already blow past our models.

[SOFIA] So the whole arc — 2020 says the biology's worth it, build the tools. 2024 says: standardize the cloning, make the tools work in the field, reduce stress to root causes. And the frontier is still out there in the ice, doing things we can't yet predict.

[DANIEL] The organisms are worth meeting. We're just finally learning the language.

[SOFIA] That's our arc. Next up, back to the single papers — stay with us.